Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Thyroid Neoplasms 1Skin Neoplasms 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1

Interventions

Cyclophosphamide 13Etoposide 10Prednisone 8Doxorubicin 8Whole-Body Irradiation 7Vincristine 7Rituximab 7Peripheral Blood Stem Cell Transplantation 7Melphalan 7Brentuximab Vedotin 7romidepsin 6fludarabine phosphate 6Mycophenolic Acid 6fludarabine 5Lenalidomide 5Gemcitabine 5Cytarabine 510-propargyl-10-deazaaminopterin 5Tacrolimus 4Granulocyte Colony-Stimulating Factor 4Carmustine 4Busulfan 4Antilymphocyte Serum 4pembrolizumab 3etoposide phosphate 3carmustine, poliferprosan 20 drug combination 3Vorinostat 3Sirolimus 3Nivolumab 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, T-Cell × Interleukin-15 × Clear all
NCT03905135 2022-09-13

Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
8 enrolled 18 charts
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡